Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy

Journal of Cardiovascular Pharmacology

Volumn 48, Issue 6, 2006, Pages 265-273

  Resende, Micheline Monteiro De ^a   Kriegel, Alison Jessica ^a   Greene, Andrew Seth ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

ACE inhibitor; Hypertrophic cardiomyopathy; Spironolactone

Indexed keywords

CAPTOPRIL; PEPTIDE; SODIUM CHLORIDE; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART INDEX; HEART MUSCLE FIBROSIS; HYPERTROPHIC CARDIOMYOPATHY; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; SALT INTAKE;

ADMINISTRATION, ORAL; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANIMALS, CONGENIC; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CAPTOPRIL; CARDIOMYOPATHY, HYPERTROPHIC; DISEASE MODELS, ANIMAL; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; INJECTIONS, SUBCUTANEOUS; MYOCARDIUM; ORGAN SIZE; RANDOM ALLOCATION; RATS; RATS, INBRED STRAINS; SPIRONOLACTONE; VENTRICULAR FUNCTION, LEFT; WEIGHT LOSS;

EID: 33846045553     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000248236.43760.86     Document Type: Article

References (59)

1. Young MJ, Funder JW. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. J Hypertens. 2002;20:1465-1468.
2. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
3. Rocha R, Chander PN, Khanna K, et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31:451-458.
4. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension. 1994;24:571-575.
5. Brilla CG. The cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertension and heart failure. Curr Opin Cardiol. 1994;1:S2-S10.
6. Cecchi F, Olivotto I, Montereggi A, et al. Prognostic value of nonsustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy. Heart. 1998;79:331-336.
7. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
8. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40:117-123.
9. Cicoira M, Zanolla L, Franceschini L, et al. Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;89:403-407.
10. Tsybouleva N, Zhang L, Chen S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004;109:1284-1291.
11. Seidman CE, Seidman JG. Molecular genetic studies of familial hypertrophic cardiomyopathy. Basic Res Cardiol. 1998;93:13-16.
12. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation. 1995;92:785-789.
13. Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes-clinical, demographic and pathological profiles. JAMA. 1996;276:199-204.
14. Semsarian C, Maron BJ. Sudden cardiac death in the young. Med J. 2002;176:148-149.
15. Semsarian C, Richmond DR. Sudden cardiac death in familial hypertrophic cardiomyopathy: an Australian experience. Aust NZ J Med. 1999;29:368-370.
16. Maron BJ, Bonow RO, Cannon III RO, et al. Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 1987;316:844-852.
17. McKenna WJ, Harris L, Perez G, et al. Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment. Br Heart J. 1981;46:173-178.
18. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J. 1985;53:412-416.
19. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose β-adrenoceptor antagonist treatment. J Am Coll Cardiol. 1999;34:1813-1822.
20. Wyatt HL, Meerbaum S, Heng MK, et al. Crosssectional echocardiography. III. Analysis of mathematic models for quantifying volume of symmetric and asymmetric left ventricles. Am Heart J. 1980;100: 821-828.
21. Rieder MJ, Roman RJ, Greene AS. Reversal of microvascular rarefaction and reduced renal mass hypertension. Hypertension. 1997;30:120-127.
22. Raff H, Hong JJ, Oaks MK, et al. Adrenocortical responses to ACTH in neonatal rats: effect of hypoxia from birth on corticosterone, StAR, and PBR. Am J Physiol Regul Integr Comp Physiol. 2003;284:R78-R85.
23. Perreault T, Baribeau J, Gosselin R, et al. Reduced vasodilator response to ANF in hypoxia-induced pulmonary hypertension in the newborn piglet. Am J Physiol. 1997;273:L289-295.
24. Kalkman EA, van Haren P, Saxena PR, et al. Early captopril prevents myocardial infarction-induced hypertrophy but not angiogenesis. Eur J Pharmacol. 1999;369:339-348.
25. Schoemaker RG, Debets JJ, Struyker-Boudier HA, et al. Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarction. J Mol Cell Cardiol. 1991;23:187-197.
26. Qi XL, Stewart DJ, Gosselin H, et al. Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. Circulation. 1999;100:1338-1345.
27. Fraccarollo D, Galuppo P, Hildemann S, et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003;42:1666-1673.
28. Kambara A, Holycross BJ, Wung P, et al. Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. J Cardiovasc Pharmacol. 2003;41:830-837.
29. Yoshiyama M, Omura T, Yoshikawa J. Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. Nippon Yakurigaku Zasshi. 2004;124:83-89.
30. Aharinejad S, Schafer R, Hofbauer R, et al. Impact of cardiac transplantation on molecular pathology of ET-1, VEGF-C, and mitochondrial metabolism and morphology in dilated versus ischemic cardiomyopathic patients. Transplantation. 2001;72:1043-1049.
31. Nicholl SM, Bell D, Spiers J, et al. Neuropeptide Y Y(1) receptor regulates protein turnover and constitutive gene expression in hypertrophying cardiomyocytes. Eur J Pharmacol. 2002;441:23-34.
32. Bell D, Allen AR, Kelso EJ, et al. Induction of hypertrophic responsiveness of cardiomyocytes to neuropeptide Y in response to pressure overload. J Pharmacol Exp Ther. 2002;303:581-591.
33. Thattaliyath BD, Livi CB, Steinhelper ME, et al. HAND1 and HAND2 are expressed in the adult-rodent heart and are modulated during cardiac hypertrophy. Biochem Biophys Res Commun. 2002;297:870-875.
34. Natarajan A, Yamagishi H, Ahmad F, et al. Human eHAND, but not dHAND, is down-regulated in cardiomyopathies. J Mol Cell Cardiol. 2001;33:1607-1614.
35. Tanabe A, Naruse M, Hara Y, et al. Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. 1: J Hypertens. 2004;22:1017-23.
36. Bauersachs J, Fraccarollo D, Ertl G, et al. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. Circulation. 2000;102:2325-8.
37. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens. 2005;18:44-9.
38. Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005;28:2106-12.
39. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart. 2004;90:765-70.
40. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-7.
41. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30-4.
42. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz. 2000;25:299-306.
43. Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens. 2003;16:80-86.
44. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
45. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;71:12A-16A.
46. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 1997;17:1152-1156.
47. Lal A, Veinot JP, Leenen FH. Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. Am J Hypertens. 2003;16:319-323.
48. Goineau S, Pape D, Guillo P, et al. Combined effects of metoprolol and spironolactone in dilated cardiomyopathic hamsters. J Cardiovasc Pharmacol. 2002;40:543-553.
49. Silvestre JS, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99:2694-2701.
50. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
51. Dzau VJ. Contributions of neuroendocrine and local autocrine-paracrine mechanisms to the pathophysiology and pharmacology of congestive heart failure. Am J Cardiol. 1988;62:76E-81E.
52. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
53. Khalil ME, Basher AW, Brown EJ Jr, et al. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol. 2001;37:1757-1764.
54. Francis GS. Neuroendocrine activity in congestive heart failure. Am J Cardiol. 1990;66:33D-38D.
55. Nakaoka H, Imataka K, Amano M, et al. Plasma levels of atrial natriuretic factor in patients with congestive heart failure. N Engl J Med. 1985;313:892-893.
56. Yasumoto K, Takata M, Ueno H, et al. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension. Am J Hypertens. 1999;12:921-924.
57. Fahy GJ, McCreery CJ, O'Sullivan F, et al. Plasma atrial natriuretic peptide is elevated in patients with hypertrophic cardiomyopathy. Int J Cardiol. 1996;55:149-155.
58. Tomoda H. [Relations of intracardiac dimensions as measured by echocardiography and plasma atrial natriuretic peptide levels in various cardiovascular diseases]. J Cardiol. 1989;19:247-255.
59. Pawlicki L, Irzmanski R, Rozalski S, et al. Correlation between left ventricular mass and the resting and post-exercise release of ANP in healthy men. Med Sci Monit. 2001;7:903-907.